Tirzepatide vs Semaglutide: Which Is Stronger?
Semaglutide and tirzepatide are both injectable weekly weight loss medications — but they work differently and produce meaningfully different results. Tirzepatide's dual-agonist mechanism targeting both GLP-1 and GIP receptors produces greater average weight loss than semaglutide's single-agonist approach. This is now confirmed in a direct head-to-head trial. Here's the full picture.
Semaglutide — GLP-1 Agonist
Activates only the GLP-1 receptor. Slows gastric emptying, increases satiety signals to the brain, improves insulin secretion in response to food. A proven, well-understood single-pathway mechanism.
Tirzepatide — GLP-1 + GIP Dual Agonist
Activates both GLP-1 and GIP receptors simultaneously. GIP (glucose-dependent insulinotropic polypeptide) adds independent appetite suppression and metabolic effects. The combination is synergistic — producing greater effect than GLP-1 alone.
GIP receptor activation was initially expected to be unfavourable for weight loss (it's an incretin that promotes fat storage in some contexts). Tirzepatide research revealed that pharmacological GIP agonism combined with GLP-1 agonism actually produces enhanced satiety and metabolic effects — a discovery that drove the clinical outcome differences seen in trials.
| Aspect | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist only | Dual GLP-1 + GIP receptor agonist ("twincretin") |
| Brand names | Ozempic (diabetes), Wegovy (obesity) | Mounjaro (diabetes), Zepbound (obesity) |
| FDA approval | Approved — diabetes (2017), obesity (2021) | Approved — diabetes (2022), obesity (2023) |
| Weight loss (clinical trials) | ~15–17% body weight (SCALE trial, 68 weeks) | ~22.5% body weight (SURMOUNT-1, 72 weeks at 15mg) |
| Injection frequency | Once weekly (subcutaneous) | Once weekly (subcutaneous) |
| Starting dose | 0.25 mg/week, titrate to 0.5–2 mg | 2.5 mg/week, titrate to 5–15 mg |
| GI side effects | Nausea, vomiting, diarrhoea, constipation (common at initiation) | Similar profile — nausea, vomiting, diarrhoea. Some evidence of slightly less nausea vs semaglutide at comparable efficacy |
| Muscle mass loss | Approximately 25–40% of weight lost is lean mass without protein optimisation | Similar concern; high protein intake remains essential |
| Cost (US, uninsured) | ~$900–1,400/month (Wegovy) | ~$1,000–1,300/month (Zepbound) |
| Head-to-head evidence | SURMOUNT-5 trial compared both directly — tirzepatide showed 20.2% vs 13.7% weight loss | Tirzepatide outperformed semaglutide in direct comparison (SURMOUNT-5, 2024) |
SCALE trial (semaglutide 2.4mg): 68-week trial in adults with obesity. Average weight loss of 14.9% body weight vs 2.4% placebo. 86.4% of participants lost at least 5% of body weight. The defining trial that established semaglutide as a major advance in pharmacological weight management.
SURMOUNT-1 trial (tirzepatide 15mg): 72-week trial. Average weight loss of 22.5% at maximum dose, 16% at 5mg. 96% of participants achieved at least 5% weight loss. A step-change above semaglutide results.
SURMOUNT-5 direct comparison (2024): The first head-to-head RCT. Tirzepatide 15mg vs semaglutide 2.4mg over 72 weeks. Results: 20.2% vs 13.7% mean weight loss — a clear, statistically significant advantage for tirzepatide.
When to prefer Semaglutide
- •More clinical data — longer track record, more long-term studies
- •Better studied for cardiovascular risk reduction (SELECT trial)
- •Slightly more prescriber familiarity and monitoring protocols established
- •May be preferred in patients with cardiac history given SELECT data
When to prefer Tirzepatide
- •Greater average weight loss — meaningful if maximum fat loss is the primary goal
- •GIP agonism adds metabolic benefits beyond GLP-1 alone
- •Similar or slightly better GI tolerability in some comparisons
- •SURMOUNT-5 direct comparison shows clear superiority for weight loss
Semaglutide & Tirzepatide — Research Grade
Available from Base Peptides for research applications.
Research and educational context. Both semaglutide and tirzepatide are FDA-approved medications available only by prescription. Research-grade versions are separate from pharmaceutical products. This article is for educational purposes.
Weight Loss Peptides Guides
Other Articles
Calculator
Calculate exact reconstitution volumes and insulin unit doses for any peptide protocol.
Open Calculator →